Latest Galeterone Stories

SAN DIEGO, Oct. 1, 2012 /PRNewswire/ -- Aragon Pharmaceuticals Inc., a leader in developing drugs for hormone driven cancers, announced new data from an ongoing, open-label, multicenter Phase II study of ARN-509, the company's 2nd generation androgen receptor antagonist, demonstrating promising results of ARN-509 in three separate patient populations with castration resistant prostate cancer (CRPC). Data were presented at the European Society for Medical Oncology 2012 Annual...

SEATTLE, Sept. 5, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that an ongoing Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer will be expanded to include an additional group of up to 25 patients whose disease has begun to progress while receiving abiraterone (Zytiga®) and prednisone. PX-866 is Oncothyreon's small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K),...